Payment overview · 2025
General Payments
$257.27
10 reported records · 7 companies
Healthcare provider profile · identity verified
Michelle R Cropper, DO
Allopathic & Osteopathic Physicians|Family Medicine · MUNCIE, IN · NPI 1669480315
Verified facts
What the public records show
CMS Open Payments records show Michelle R Cropper, DO received $257.27 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.04 | 35.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.52 | 19.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.78 | 17.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.32 | 8.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 7.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.22 | 6.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.54 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.42 | 9 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $91.04 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 456 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 66 |
| Lisinopril | Lisinopril | 196 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 48 |
| Losartan Potassium | Losartan Potassium | 156 | 43 |
| Omeprazole | Omeprazole | 156 | 43 |
| Gabapentin | Gabapentin | 155 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 45 |
| Montelukast Sodium | Montelukast Sodium | 129 | 28 |
| Metformin Hcl Er | Metformin Hcl | 125 | 32 |
| Simvastatin | Simvastatin | 122 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 31 |
| Alprazolam | Alprazolam | 115 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 33 |
| Synthroid | Levothyroxine Sodium | 111 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 16 |
| Carvedilol | Carvedilol | 108 | 25 |
| Furosemide | Furosemide | 104 | 36 |
| Potassium Chloride | Potassium Chloride | 101 | 28 |
| Alendronate Sodium | Alendronate Sodium | 100 | 29 |
| Eliquis | Apixaban | 96 | 25 |
| Trazodone Hcl | Trazodone Hcl | 93 | 31 |
| Allopurinol | Allopurinol | 85 | 19 |
| Benazepril Hcl | Benazepril Hcl | 85 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 26 |
| Valsartan | Valsartan | 80 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 15 |
| Buspirone Hcl | Buspirone Hcl | 74 | 23 |
| Clonazepam | Clonazepam | 73 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 14 |
| Tramadol Hcl | Tramadol Hcl | 71 | 25 |
| Meloxicam | Meloxicam | 68 | 18 |
| Jardiance | Empagliflozin | 67 | 12 |
| Metformin Hcl | Metformin Hcl | 63 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 20 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | suppressed |
| Ozempic | Semaglutide | 53 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 37 |
| Sertraline Hcl | Sertraline Hcl | 48 | 14 |
| Bupropion Xl | Bupropion Hcl | 47 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 47 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 12 |
| Irbesartan | Irbesartan | 41 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 17 |
| Topiramate | Topiramate | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 31 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 11 |
| Torsemide | Torsemide | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 17 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Lubiprostone | Lubiprostone | 31 | suppressed |
| Prednisone | Prednisone | 31 | 16 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 18 |
| Nystatin | Nystatin | 21 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 12 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Digoxin | Digoxin | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Topiramate Er | Topiramate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $257.27 · 10 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, ELIQUIS, JARDIANCE, NURTEC ODT, SHINGRIX, VENASEAL, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error